PDF(1184 KB)
Changes in plasma levels of atrial natriuretic peptide, endothelin-1 and von Willebrand factor among newborns with persistent pulmonary hypertension
YAO Ai-Min, HAO Ya-Ping, ZHANG Jie, SUN Xue-Jiang, WANG Hong-Ying, LI Bin, LI Jian-Ling
Chinese Journal of Contemporary Pediatrics ›› 2013, Vol. 15 ›› Issue (9) : 718-722.
PDF(1184 KB)
PDF(1184 KB)
Changes in plasma levels of atrial natriuretic peptide, endothelin-1 and von Willebrand factor among newborns with persistent pulmonary hypertension
Objective To investigate the changes in plasma levels of atrial natriuretic peptide (ANP), endothelin-1 (ET-1) and von Willebrand factor (vWF), and their significance among newborns with persistent pulmonary hypertension (PPH). Methods Sixty-six newborns with PPH (case group) (mild: 26 cases; moderate: 21 cases; severe: 19 cases), as well as 40 newborns without PPH (control group) who were hospitalized in the same period, were enrolled. The control group underwent echocardiography on admission. The case group underwent echocardiography before treatment (with refractory hypoxemia) and after 7 days of treatment for measurement of pulmonary artery systolic pressure (PASP). Meanwhile, plasma levels of ANP, ET-1 and vWF were measured using ELISA. Results Before treatment, the case group had significantly higher plasma levels of ANP, ET-1 and vWF than the control group (P<0.05), and these indices increased as PASP rose. After 7 days of treatment, the children with mild or moderate PPH showed normal PASP, and their plasma levels of ANP, ET-1 and vWF were not significantly different from those of control group. The children with severe PPH had significant decreases in all indices, but they were significantly higher than those of the control group. Plasma levels of ANP, ET-1 and vWF were significantly positively correlated with PASP before and after treatment (P<0.01). Conclusions Changes in plasma levels of ANP, ET-1 and vWF can reflect PASP in newborns with PPH during treatment. Dynamic monitoring of these indices can help to judge the severity of PPH and guide treatment.
Persistent pulmonary hypertension / Atrial natriuretic peptide / Endothelin-1 / von Willebrand factor / Newborn
[1] 王莉, 朱艳萍, 李明霞. HIF-1、ET-1、iNOS在新生儿缺氧性肺动脉高压发病中的作用[J].中国当代儿科杂志, 2011, 13(1): 8-11.
[2] 葛毅萍, 廉哲勋, 刘芳, 谭凯. NECA对兔急性心肌缺血再灌注后vWF水平的影响[J].实用心脑肺血管病杂志, 2008, 16(1): 1-4.
[3] 孙景辉, 孙华, 刘延波, 刘桂英, 翟淑波, 李秋菊.人类心房利钠肽基因在自发性高血压大鼠体内的表达及其影响[J].临床儿科杂志, 2007, 25(10): 857-860
[4] Helset E, Kjaeve J, Bjertnaes L. Acute alveolar hypoxia increases endothelin-1 release but decreases release of calcitonin generelated peptide in isolated perfused rat lungs[J]. Sand J Clin Lab Invest, 1995, 55: 369-376.
[5] 杜立中,魏克伦,孙眉月.新生儿持续肺动脉高压的诊断常规[J].中华儿科杂志, 2002, 40(7): 438-439.
[6] Abman SH. Recent advances in the pathogenesis and treatment of persistent pul-monary hypertension of the newborn［J］. Neonatology, 2007, 91(4): 283-290.
[7] 王红,张永红,李明霞.缺氧性肺动脉高压发病机制研究进展[J].中国实用儿科杂志, 2009, 24(3): 227-230.
[8] Kangawa K, Matsuo H. Purification and complete aminoaeid Sequence of alpha-human atrial natriuretic polypeptide(alpha-hANP)[J]. Biochem Biophys Res Commun, 1984, 118(1): 131.
[9] Vaz Perez A, Doehner W, Von Haehling S. The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure[J]. Int J Cardiol, 2010, 141 (1): 39-43.
[10] Gerczuk PZ, Kloner RA. An update on cardioprotection a review of the latest adjunctive therapies to limit myocardial infarcction size in clinical trials[J]. J Am Coll Cardiol, 2012, 59 (11): 970-978.
[11] Koga H, Hagiwara S, Kusaka J, Matsumoto S, Nishida T, Yokoi I, et al. Human atrial natriuretic peptide attenuates renal ischemia-reperfusion injury[J]. J Surg Res, 2012, 173(2): 348-353.
[12] Krishnan U. Management of Pulmonary Arterial Hypertension in the Neonatal Unit[J]. Cardiol Rev, 2010, 18(2): 73-75.
[13] 窦常胜, 叶彩宏, 张士发, 睢燕, 周名雄, 刘永芳, 等.先天性心脏病合并肺动脉高压患儿血浆内皮素、降钙素基因相关肽的临床研究[J].临床儿科杂志, 2010, 28(7): 621-623.
[14] 王学英, 王胜昱.慢性阻塞性肺疾病继发肺动脉高压患者血清中C 反应蛋白和内皮素-1的表达及研究[J].山西医科大学学报, 2012, 43(6): 444-446.
[15] 周英, 王乐, 李明霞.缺氧性肺动脉高压新生儿血清HIF-1α、ET-1及Ca2+ 变化及意义[J].中国当代儿科杂志, 2011, 13(3): 181-184.
[16] Giaid A, Yanagisawa M, Langleben D. Expression of endothelin-1 in the lungs of patients with pulmona hypertension[J]. N Engl J Med, 1993, 328(24): 1732-1739.
[17] 王亚洲, 黄丽萍, 黄萍, 陈玉君.低氧新生鼠肺组织中内皮素转化酶-1的表达[J].中国新生儿科杂志, 2012, 27(2): 128-129.
[18] Blann AD, T abemer DA. A reliable marker ofendothelial cell dysfunction: Does it exist?[J]. Br JHaematol, 1995, 90(2): 244-248.
[19] 庄梅, 韩国栋, 罗红鹤, 魏民新, 伍联近, 孙培吾, 等.先天性心脏病合并肺高压患者血循环中vWF相关抗原的表达[J].中山医科大学学报, 2002, 23(6): 455-457.
[20] Lopes AA, Barreto AC, Maeda NY, Cicero C, Soares RPS, Bydlowski SP. et al. Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease[J]. Brazil J Med Biol Res, 2011, 44(12): 1269-1275.
[21] Alian Z, Hashemipour M, Dehkordi EH, Hovsepian S, Amini M, Moadab MH, et al. The effects of folic acid on markers of endothelial function in patients with type1 diabetes mellitus[J]. MED ARH, 2012, 66(2): 12-15.
[22] Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease[J]. Thromb Haemost, 2006, 4(11): 86-93.
[23] 洪欣, 李凤芝, 尹昭云, 颜培华, 何一心. 不同应激损伤所致血管内皮细胞中vWF的变化[ J].中国应用生理学杂志, 2000, 16(4): 31.
